ALNY News and Press, Alnylam Pharmaceuticals Inc. From 08/28/23

2023-08-28 16:16:00 ET More on Alnylam Pharmaceuticals Alnylam: Unlimited Promise Or Unlimited Losses? Alnylam: Zilebesiran Deal With Roche Reveals A Very Long Development Timeline Roche, Alnylam in pact for blood pressure candidate Alnylam to face FDA AdCom ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced an update on its ongoing patent infringement litigation. On March 17, 2022, Alnylam initiated litigation in the United States District Court for the District of Delaware against Moderna for pate...

2023-08-18 14:23:01 ET More on Regeneron Pharmaceuticals Regeneron could see share price bounce with potential approvals Regeneron: CRL For High Dose Eylea Gives Vabysmo A Wider Opening Regeneron Pharmaceuticals: Overdependence On Eylea Brought To The Forefro...

2023-08-08 07:30:00 ET Summary Alnylam's shares have seen significant growth, up over 140% since September 2019. The company has secured approvals for five RNAi drugs and aims to become a top-tier biotech company by 2025. The success of its RNAi therapeutics and potential futu...

2023-08-03 13:40:06 ET Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2023 Earnings Conference Call August 3, 2023, 8:30 AM ET Company Participants Christine Lindenboom - Senior Vice President-Investor Relations and Corporate Communication Yvonne Greenstreet - Chief Executi...

2023-08-03 08:29:48 ET Alnylam Pharmaceuticals press release ( NASDAQ: ALNY ): Q2 Non-GAAP EPS of -$1.62 misses by $0.28 . Revenue of $318.75M (+41.8% Y/Y) misses by $31.82M . For further details see: Alnylam Pharmaceuticals Non-GAAP EPS of -$1.62 misses ...

2023-08-02 13:41:55 ET Alnylam Pharmaceuticals ( NASDAQ: ALNY ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is -$1.34 (+34.0% Y/Y) and the consensus Revenue Estimate is $350.57M (+55.9% Y/Y). Over...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 43 rd Annual Growth Conference on Thursday, August 10, 2023 at 10:30 am ET at the InterContinental Hotel in Boston. ...

2023-07-30 09:05:25 ET Summary Alnylam partnered Roche to develop and commercialize zilebesiran for the treatment of hypertension. Alnylam's share price has not benefited as the announcement was followed by the company revealing a very long development timeline for the candidate. ...

– Partnership Combines Alnylam’s Leadership in RNAi Therapeutics with Roche’s Proven Track Record of Successfully Developing and Launching Innovative Medicines Worldwide – – Zilebesiran Represents a Potentially Transformative Approach to Reducing CV ...